Researchers Develop Self-Medicating Surgical Stitches to Reduce Inflammation and Prevent Tissue Death

Researchers develop electrospun surgical sutures that slowly release anti-inflammatory drugs, reducing scarring and improving blood vessel surgery outcomes.

By: AXL Media

Published: Mar 24, 2026, 9:10 AM EDT

Source: Information for this report was sourced from American Chemical Society

Targeting the Biological Risks of Traditional Suturing

Deep surgical incisions currently require a dual approach to healing: physical closure through stitches and systemic pain management through oral anti-inflammatories like ibuprofen. However, oral medications often fail to reach the specific injury site in sufficient concentrations to prevent localized inflammation. This oversight can lead to "anastomosis failure," where inflamed blood vessels close up, causing the death of surrounding tissue or the reopening of wounds. Inspired by personal family medical experiences, researcher Mieya Kirby and chemist Sharon K. Hamilton are developing sutures that eliminate this risk by delivering medication precisely where the needle meets the skin.

The Innovation of Electrospun Nanofibers in Wound Care

The foundation of this new technology lies in electrospun polymers, a material that can be drawn into delicate nanofibers under high voltage. These fibers provide an ideal surface for regenerating tissues and can be molded into various medical shapes, including flexible, dissolvable stitches. The researchers utilized polydioxanone (PDO), a well-established biodegradable polymer that maintains its structural integrity for several weeks before being naturally metabolized by the body. While previous attempts to coat these fibers in medicine resulted in the drugs washing away too quickly, the Ouachita Baptist team has introduced a chemical solution to ensure a steady, prolonged release.

Covalent Bonding and the Science of Controlled Release

To solve the "quick-release" problem that plagues traditional drug-coated stitches, the team blended PDO with a secondary polymer capable of forming covalent bonds with non-steroidal anti-inflammatory drugs (NSAIDs). Unlike simple dipping methods, these chemical bonds are designed to break down gradually under physiological conditions. This controlled degradation ensures that the anti-inflammatory medication is released over a period of weeks rather than hours. This timing is critical because the body begins laying down new collagen between the second and fourth week of healing; releasing too much medication too early can actually interfere with this vital structural protein.